U.S. markets close in 3 hours 38 minutes
  • S&P 500

    4,163.72
    -21.75 (-0.52%)
     
  • Dow 30

    34,063.58
    -137.09 (-0.40%)
     
  • Nasdaq

    13,904.53
    -147.81 (-1.05%)
     
  • Russell 2000

    2,222.52
    -40.15 (-1.77%)
     
  • Crude Oil

    63.36
    +0.23 (+0.36%)
     
  • Gold

    1,771.90
    -8.30 (-0.47%)
     
  • Silver

    25.82
    -0.28 (-1.09%)
     
  • EUR/USD

    1.2038
    +0.0058 (+0.48%)
     
  • 10-Yr Bond

    1.5870
    +0.0140 (+0.89%)
     
  • GBP/USD

    1.3981
    +0.0142 (+1.02%)
     
  • USD/JPY

    108.0740
    -0.7090 (-0.65%)
     
  • BTC-USD

    55,413.64
    -32.09 (-0.06%)
     
  • CMC Crypto 200

    1,248.02
    -50.94 (-3.92%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S.

  • The FDA has indicated Libtayo for treating previously-treated, advanced BCC patients who have already received a hedgehog pathway inhibitor (HHI) or who cannot be treated with an HHI.

  • The PD-1 inhibitor has been granted full approval for patients with locally advanced BCC and accelerated approval for patients with metastatic BCC, which has spread to other parts of the body.

  • In 2018, Libtayo was approved as the first systemic treatment for metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

  • Price Action: REGN closed 0.8% down at $490.68, while, SNY closed 0.5% higher at $48.86.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.